Keyword: Christophe Weber

Takeda will probably not sell its OTC business to help pay off the $31 billion loan it’s taking to finance the Shire takeover, its CEO says.

The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.

With a critical shareholder vote looming, Takeda's CFO says the company will consider selling up to $10 billion in assets to help fund its Shire buy.

Takeda CEO Christophe Weber and Nissan's now-fallen chairman Carlos Ghosn have much more in common than their French nationality.

Ahead of an early December shareholder vote on Takeda's Shire buyout, some Takeda investors and insiders are working to gather support against it.

Takeda is eager to close its Shire deal and take the specialty pharma under its wing, but for now it's highlighting a few strengths in its own business.

Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.

Takeda's CEO has said Ninlaro would surpass blockbuster Velcade as the company’s biggest-ever cancer product. But NICE could get in the way.

Takeda's blockbuster cancer med Velcade, previously set for copycat competition this year, won an appeals court ruling preserving sales for years.

With a patent loss looming, Takeda filed a citizen petition pushing the FDA to knock back generic Velcade competition.